Table 1.
Characteristics of cohorts included into the study. Cohort #1 (n = 14, transcriptome analysis), Cohort #2 (n = 71, TLDA-PCR).
| Cohort #1 (Transcriptome) n = 14 | Cohort #2 (TLDA PCR) n = 71 | |||||
|---|---|---|---|---|---|---|
| ID | Non-ID | ID | Non-ID | |||
| N = 7 | N = 7 | P-Value | N = 35 | N = 36 | p-Value | |
| Demographic and Clinical Factors | ||||||
| Age, years | 70 (9) | 71 (10) | 0.762 | 70 (12) | 72 (11) | 0.472 |
| Sex (male), n (%) | 6 (86) | 6 (86) | 1.0 | 23 (64) | 22 (63) | 1.0 |
| Systolic blood pressure, mmHg | 135 (19) | 124 (22) | 0.309 | 123 (20) | 120 (17) | 0.495 |
| NYHA functional class | ||||||
| I-II | 5 (71) | 5 (71) | 1.0 | |||
| III-IV | 2 (29) | 2 (29) | ||||
| LVEF, % | 36 (5) | 35 (6) | 0.772 | 33 (7) | 34 (6) | 0.908 |
| Ischemic etiology of HF, n (%) | 5 (71) | 5 (71) | 1.0 | 22 (61) | 18 (51) | 0.477 |
| 6 mwt distance | 248 (138) | 287 (155) | 0.618 | 230 (141) | 257 (172) | 0.488 |
| Comorbidities | ||||||
| Hypertension, n (%) | 6 (86) | 6 (86) | 1.0 | 29 (81) | 27 (77) | 0.778 |
| Diabetes Mellitus, n (%) | 5 (71) | 2 (29) | 0.286 | 28 (78) | 18 (51) | 0.026 |
| Previous MI, n (%) | 2 (29) | 2 (29) | 1.0 | 11 (31) | 9 (26) | 0.793 |
| CKD a, n (%) | 2 (29) | 2 (29) | 1.0 | 16 (44) | 17 (49) | 0.814 |
| Anemia WHO, n (%) | 3 (43) | 2 (29) | 1.0 | 23 (64) | 21 (60) | 0.809 |
| Anemia, Hb < 12 g/dL, n (%) | 0 (0) | 0 (0) | 1.0 | 16 (44) | 13 (37) | 0.631 |
| Comorbidity index | 3 (1) | 3 (1) | 1.0 | 4 (1) | 3 (1) | 0.266 |
| Treatments (%) | ||||||
| ACEI or ARBs | 5 (71) | 5 (71) | 1.0 | 24 (67) | 27 (77) | 0.430 |
| Beta-blockers | 6 (86) | 5 (71) | 1.0 | 34 (94) | 32 (91) | 0.674 |
| Diuretics | 7 (100) | 6 (86) | 1.0 | 32 (89) | 31 (89) | 1.0 |
| Laboratory | ||||||
| Hemoglobin, g/dL | 13.6 (1.2) | 13.4 (0.6) | 0.645 | 11.9 (1.5) | 12.2 (1.3) | 0.321 |
| eGFR, ml/min/1.73 m2 | 65 (21) | 65 (19) | 0.975 | 67 (28) | 65 (33) | 0.839 |
| NT-proBNP, pg/mL | 1574 (497–1028) | 536 (481–1178) | 0.318 | 1892 (832–4776) | 1450 (536–5901) | 0.890 |
| hs-CRP | 0.4 (0.2–1.4) | 0.5 (0.2–6.2) | 0.628 | 0.6 (0.3–1.4) | 0.3 (0.2–0.9) | 0.086 |
| Iron status and hematinic | ||||||
| Serum iron | 50.9 (9.2) | 85.3 (29.3) | 0.012 | 45.8 (17.2) | 89.6 (32.8) | <0.001 |
| Serum ferritin | 57.3 (32.2) | 262.0 (132.8) | 0.002 | 45.4 (26.9) | 322.9 (238.8) | <0.001 |
| TSAT | 13.2 (2.0) | 25.4 (6.3) | <0.001 | 11.4 (3.6) | 27.1 (10.7) | <0.001 |
| sTfR | 2.1 (0.4) | 1.5 (0.8) | 0.095 | 2.0 (0.6) | 1.2 (0.4) | <0.001 |
Data presented as mean ± SD, N (%) or median (interquartile range). ACEI (angiotensin converting enzyme inhibitor), ARB (angiotensin receptor blocker), BMI (body mass index), BP (blood pressure), CKD (chronic kidney disease), HF (heart failure), Hb (Hemoglobin), COPD (chronic obstructive pulmonary disease), eGFR (estimated glomerular filtration rate), hs-CPR (high sensitive reactive c protein), LVEF (left ventricular ejection fraction), MRA (mineralocorticoid receptor antagonist), NT-proBNP (N-terminal pro-B type natriuretic peptide), NYHA (New York Heart Association), sTfR (serum soluble transferrin receptor), TSAT (transferrin saturation), WHO (world health organization). a CKD was defined as eGFR < 60 (MDRD).